Business Wire

Galvanize Climate Solutions Closes Over $1 Billion for First Venture and Growth Equity Fund

14.9.2023 15:00:00 EEST | Business Wire | Press release

Share

Galvanize Climate Solutions (“Galvanize”), a global climate-focused investment firm, today announced the final close of its Innovation + Expansion Fund (“the Fund”) at over $1 billion. With commitments from a diverse set of institutional investors, including leading endowments, foundations and family offices, the Fund is one of the largest climate venture funds raised to date. The Fund targets investments in early- to growth- stage climate companies that drive timely decarbonization, providing both capital as well as interdisciplinary resources to help accelerate the path to commercial scale.

Founded by seasoned investors with decades of collective experience working in the climate ecosystem, Galvanize is purpose-built to scale the defining climate companies of our generation. To this end, Galvanize has assembled a veteran investment team augmented by in-house experts in disciplines vital to climate company builders - including climate science and technology, regulatory affairs, market development, impact measurement, and talent acquisition. With these resources, the Fund is distinctly positioned to identify, evaluate, and amplify transformative climate companies.

“Fully realizing the most significant investment opportunity of our time and succeeding in ushering in the climate transition will require more than capital alone,” said Tom Steyer, Co-Executive Chair of Galvanize, who previously founded and ran one of the first multi-strategy global investment firms, Farallon Capital Management, which grew to over $36 billion in assets under management under his leadership. “That’s why, based on years of investment experience and an understanding of the resources needed to accelerate critical climate solutions, we deliberately built Galvanize to forge a new model for climate investing, alongside constructing a world-class team built for this moment. We are thrilled to have the support of our partners in pursuit of this opportunity.”

The Fund is led by Veery Maxwell, Saloni Multani and Cliff Ryan, who collectively bring deep climate expertise coupled with a history of building and managing multi-billion dollar investment strategies at leading global firms, including Hellman & Friedman and Riverstone Holdings.

“We are witnessing an inflection point in the transformation of the global economy,” said Saloni Multani, co-head of Innovation + Expansion at Galvanize. “The alignment of market forces – including corporate commitments, regulatory and policy progress, consumer expectations, workforce talent preferences, technological maturation and economic competitiveness – is driving substantial tailwinds behind the climate sector. We believe immense value will accrue to the technologies and solutions that can drive meaningful decarbonization over the next decade.”

With its climate-focused, integrated model, the Fund takes an interdisciplinary approach across the full cycle of an investment, providing a differentiated set of resources to advantage the companies in its portfolio and create long-term value for its investors. This includes facilitating priority customer introductions, assisting talent recruitment, and providing regulatory analysis and guidance. Members of Galvanize’s portfolio services team have previously held roles at ARPA-E, the National Renewable Energy Laboratory and the White House Council on Environmental Quality, among other leading climate, technology and government organizations.

To-date, the fund has invested in 11 companies across the electricity, transport, industry, buildings, agriculture and carbon removal sectors: alcemy, Arable, Lydian, Plotlogic, Pulsora, Regrow, The Routing Company, VEIR, Watershed, Worldly and Zhero.

ABOUT GALVANIZE CLIMATE SOLUTIONS

Galvanize Climate Solutions (“Galvanize”) is a climate-focused global investment firm delivering capital and expertise to accelerate climate solutions. Founded by Katie Hall and Tom Steyer, Galvanize invests across asset classes including venture capital and growth equity, public equities, and real estate. We integrate expertise across investment, climate impact, measurement, market development, talent, technology, and policy with the aim of driving material climate impact and creating long-term value for our investors.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

press@galvanizeclimate.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release

PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release

Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release

Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye